Company: HRTX
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0000950170-25-107416
Chunk: 1

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-08-12
Form: 8-K
Item: Item 5.03
Chunk 1
---
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Certificate of Designation of Series A Convertible Preferred Stock

Pursuant to authority expressly vested in the Board by the Company’s certificate of incorporation, as amended (the “ Certificate of Incorporation”), the Board authorized and the Company filed, on August 11, 2025, the Certificate of Designation of Rights, Preferences and Privileges (the “ Certificate of Designation’) of Series A Convertible Preferred Stock, par value $0.01 per share (the “ Series A Convertible Preferred Stock”), with the Secretary of State of the State of Delaware. The Certificate of Designation sets forth the rights, preferences, powers, designations, restrictions and limitations of the Series A Convertible Preferred Stock.

The following is a summary of key terms of the Series A Convertible Preferred Stock:

Designation and Amount. A total of 524,141 shares of Series A Convertible Preferred Stock are authorized for issuance under the Certificate of Designation. The shares of Series A Convertible Preferred Stock have a stated value of $15.00 per share and are convertible into shares of the Company’s common stock, par value $0.01 per share (the “ Common Stock”), at a conversion price of $1.50 per share, subject to certain adjustments.

Dividends. Holders of Series A Convertible Preferred Stock are entitled to dividends on an as-if-converted basis in the same form as any dividends actually paid on shares of Common Stock or other securities of the Company.

Ranking. The Series A Convertible Preferred Stock will rank senior to Common Stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company.

Voting Rights. Except as otherwise required by law, the holders of Series A Convertible Preferred Stock have no right to vote on matters submitted to a vote of the Company’s stockholders. Without the prior written consent of a majority of the outstanding shares of Series A Convertible Preferred Stock, the Company may not: (i) amend its Certificate of Incorporation (including the Certificate of Designation) in a manner adverse to the Series A Convertible Preferred Stock; (ii) create or authorize the creation of any other security convertible into or exercisable for any equity security

ranking as to dividends, redemption or distribution of assets upon a liquidation senior to, the Series A Convertible Preferred Stock, or increase the authorized number of